GH Research PLC Ordinary Shares

GHRS XNAS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

1.7B

Short interest (May 15)

3.1%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.65%

↓ 6.5%

Available Shares

200K

↑ 28.0%

Price Chart

Company Overview

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Company Info

Exchange: NASDAQ

CIK: 0001855129

Asset Type: CS

Market Data

Market Cap: $1,706,303,815

Employees: 73

Status: Active

Short Interest

Current Borrow Fee 0.65%

Range: 0.65% - 0.65%

Available Shares 200K

Range: 200K - 200K

Recent Changes

Fee Change: ↓ 3.8%

Available Change: ↑ 80.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime